[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.203.142. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,765
Citations 0
Viewpoint
November 7, 2019

Neuroendocrine Tumors—Less Well Known, Often Misunderstood, and Rapidly Growing in Incidence

Author Affiliations
  • 1Division of Medical Oncology, Department of Internal Medicine, University of Kentucky, Lexington
  • 2Neuroendocrine and Gynecologic Cancer Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • 3Medical Oncology and Clinical Endocrinology, Center for Cancer Research Rare Tumor Clinic, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
JAMA Oncol. Published online November 7, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.4568

Cancer is a great equalizer; it does not differentiate between rich or poor, young or old. The history of cancer is as ancient as the origins of humans and continues to be an enigma in the 21st century. Much has been uncovered about the causes of various cancers, and tremendous advances in both diagnostics and therapeutics have occurred. Indeed, patients with cancer today are living longer and with a better quality of life, and the horizon looks even more promising. However, one supposedly rare neoplastic condition called neuroendocrine tumor (NET) is often ceded to obscurity by academia, the pharmaceutical industry, health care policy makers, and media. Although celebrities, including Steve Jobs and Aretha Franklin, have received diagnoses of NET, public awareness about this condition has been lacking.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    A noteworthy increase in incidence shouldn't go without pursuit of explanation
    Diana T Chingos, MS, MFA, | Independent Cancer Patient Advocate
    You wrote: "The 7-fold increase in incidence is noteworthy, and if the current trend continues, we will be obligated to look into environmental factors that might be contributing to this increase." Why isn't a 7-fold increase in incidence in itself an obligation to look into environmental factors that might be contributing to this increase?
    CONFLICT OF INTEREST: None Reported
    ×